- Apr 19, 2018 -
Pharmaceutical intermediates product line in our country, based bulk drug intermediates, upstream in the product due to the application field is wide, occupy the advantage position of the chain, that result in a rapid development and also in the market.
However, the export of pharmaceutical intermediates in China has come under pressure from other countries, especially India. India's rapid rise in the pharmaceutical industry is now associated with competition and symbiosis with our country. It has been proved that the impact from India is not negligible in the European Union, North America, Middle East, southeast Asia, etc., which is the main export area of pharmaceutical intermediates in China.
Therefore, China's pharmaceutical intermediate industry must adjust export strategy. Experts believe that the choice of competitive intermediates may be an effective breakthrough.
In particular, sulfonamides, tetracycline, analgin and other commodities are the early ones in China. With the passage of time, China's pharmaceutical intermediates have developed rapidly, and we can see our advantages from the current share of the global market share. Such as VC, penicillin, citric acid, phenol of acetamide group and acetaminophen accounted for more than 60% of the global share, such as amoxicillin, ceftriaxone, ibuprofen, aspirin, etc are all influential products around the world. On product categories, anti-infection drugs, vitamins, antipyretic analgesics, is China's export-oriented API series such as amino acid, total API by more than 90% of the total, and the corresponding intermediate domestic demand is also larger.
Experts also remind the relevant pharmaceutical intermediates that the research and production of pharmaceutical intermediates should be adjusted as the situation progresses. Experts believe that the changes in the disease spectrum will create new fields in the pharmaceutical market, and the corresponding medical intermediates will also change, resulting in new opportunities.